JP2024542728A5 - - Google Patents

Info

Publication number
JP2024542728A5
JP2024542728A5 JP2024532709A JP2024532709A JP2024542728A5 JP 2024542728 A5 JP2024542728 A5 JP 2024542728A5 JP 2024532709 A JP2024532709 A JP 2024532709A JP 2024532709 A JP2024532709 A JP 2024532709A JP 2024542728 A5 JP2024542728 A5 JP 2024542728A5
Authority
JP
Japan
Prior art keywords
formula
sirna molecule
nucleotides
represented
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542728A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080766 external-priority patent/WO2023102490A1/en
Publication of JP2024542728A publication Critical patent/JP2024542728A/ja
Publication of JP2024542728A5 publication Critical patent/JP2024542728A5/ja
Pending legal-status Critical Current

Links

JP2024532709A 2021-12-01 2022-12-01 てんかんの治療のための組成物及び方法 Pending JP2024542728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284932P 2021-12-01 2021-12-01
US63/284,932 2021-12-01
PCT/US2022/080766 WO2023102490A1 (en) 2021-12-01 2022-12-01 Compositions and methods for treatment of epilepsies

Publications (2)

Publication Number Publication Date
JP2024542728A JP2024542728A (ja) 2024-11-15
JP2024542728A5 true JP2024542728A5 (https=) 2025-12-08

Family

ID=86613118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532709A Pending JP2024542728A (ja) 2021-12-01 2022-12-01 てんかんの治療のための組成物及び方法

Country Status (8)

Country Link
EP (1) EP4441229A1 (https=)
JP (1) JP2024542728A (https=)
KR (1) KR20240159663A (https=)
CN (1) CN118974255A (https=)
AU (1) AU2022402159A1 (https=)
CA (1) CA3241122A1 (https=)
MX (1) MX2024006709A (https=)
WO (1) WO2023102490A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019157531A1 (en) * 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
AU2019406186A1 (en) * 2018-12-20 2021-07-15 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of KCNT1 related disorders
CR20210519A (es) * 2019-03-15 2021-11-24 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de kcnt1

Similar Documents

Publication Publication Date Title
JP2016530882A5 (https=)
EP3484524B1 (en) Compounds and methods for modulation of smn2
JP2019141097A5 (https=)
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2024109582A (ja) トリループを含む二本鎖核酸インヒビター分子
JP2024536146A (ja) アンジオテンシノーゲンを調節する組成物及びその使用方法
JP2024542738A5 (https=)
KR20250125967A (ko) 진보된 rna 표적화 (arnatar)
AU2017297624B2 (en) Compounds and methods for modulation of transcript processing
JP2024542728A5 (https=)
TW202329983A (zh) Rna編輯
CN119137272A (zh) 血管紧张素原调节组合物和其使用方法
CN119698475A (zh) 血管紧张素原的高效rna靶向(arnatar)
WO2020038973A1 (en) Antisense oligonucleotides targeting sptlc1
TW202309286A (zh) 作為新穎基因靜默技術的非對稱短雙股dna及其應用
TW202313977A (zh) 作為新穎基因靜默技術的短雙股dna及其應用
JP2024520556A5 (https=)
JP2024512612A5 (https=)
JPWO2022138787A5 (https=)
JP2024520555A5 (https=)
CA3135794A1 (en) Angptl2 antisense oligonucleotides and uses thereof
ES3014830A1 (es) Oligonucleotidos o analogos de los mismos para el tratamiento de la distrofia del endotelio corneal de fuchs
EP4705457A2 (en) Oligonucleotides capable of upregulating glucocerebrosidase expression
CN118489009A (zh) 寡核苷酸gba激动剂
CN118541484A (zh) 反义寡核苷酸